About

Focal segmental glomerulosclerosis (FSGS) is a serious kidney disease where scarring damages the organ's filters, leading to harmful protein loss and often progressing to kidney failure. Filspari (sparsentan) is a once-daily pill that works by blocking two key hormone pathways that contribute to this scarring and protein leak. By targeting these dual mechanisms, it may help reduce protein loss and protect long-term kidney function better than older standard therapies.